Diabetes has emerged as a major economic burden with high associated human and financial cost. It a chronic disease affecting millions of population globally every year. Insulin is administered to the diabetic patient using various insulin delivery devices; out of these insulin pen is the most preferred option. The report “Global Insulin Market – Focus on Insulin Delivery Devices Market Outlook 2022” provides an in-depth analysis of global insulin therapy market, focusing on insulin delivery devices such as vial and syringes, insulin pen, insulin pump, etc.
The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities at the global and regional level. The report has been segmented as following:-
Market Segmentation
• Insulin Market
• Insulin Delivery Devices Market
Market Segmentation by Geography
• Europe
• North America and Caribbean
• China
Key Vendors
• Novo Nordisk
• Sanofi Aventis
• Eli Lilly and Company
• Merck and Company
1. Executive Summary
2. Research Methodology
3. Introduction
4. Diabetes
4.1.1 Overview
4.1.2 Cost – Human & Financial
5. Insulin Market
5.1 Overview
5.2 Market Analysis
5.2.1 Market Sizing (Actual & Forecasted)
5.2.2 Market Share by Insulin Type
5.2.3 Market Share by Segment
5.2.4 Market Share by Region
6. Insulin Delivery Devices
6.1 Overview
6.2 Vial and syringe
6.2.1 Overview
6.2.2 Market Sizing (Actual & Forecasted)
6.3 Insulin pen
6.3.1 Overview
6.3.2 Market Sizing (Actual & Forecasted)
6.4 Insulin Pump
6.4.1Overview
6.4.1 Market Sizing (Actual & Forecasted)
6.5 Others
6.6 Market Share Analysis
6.6.1 Market Share by Devices
6.6.2 Market Share by End-User
6.6.3 Market Share by Region
7. Regional/ Country Analysis
7.1 Europe
7.1.1 Overview
7.1.2 Market Sizing (Actual & Forecasted)
7.1.3 Market Share
7.2 North America and Caribbean
7.2.1 Overview
7.2.2 Market Sizing (Actual & Forecasted)
7.2.3 Market Share
7.4 China
7.4.1 Overview
7.4.2 Market Sizing (Actual & Forecasted)
7.4.3 Market Share
8. Pricing Analysis
9. Global Insulin Market Dynamics
9.1 Industry Trends & Developments
9.1.1 Dominance of Modern and New-Generation Insulin
9.1.2 Advent of Intelligent Insulin Pens
9.1.3 Sensor-augmented Pump Therapy
9.1.4 Approval of Glargine Basaglar – The First “Biosimilar” Insulin in the US
9.3 Growth Drivers
9.3.1 Increasing Prevelance of Diabetes
9.3.2 Rise in Geriatric Population
9.3.3 Growing Obese Population
9.3.4 Propogation of Diabetes Management Awareness
9.3.5 Government Impetus
9.4 Challenges
9.4.1 High Cost of Insulin
9.4.2 Insurance Coverage issue
9.4.3 High Competition
9.4.4 Regulatory Pressure
10. Competitive Landscape
10.1 Market Share by Competitors
10.2 Market Share by Drug Brands
11. Company Profiles
11.1 Novo Nordisk
11.2 Sanofi Aventis
11.3 Eli Lilly and Company
11.4 Merck & Co.
List of Tables
Table 1: Insulin and Diabetes Drugs Approved Between 2012-2016
Table 2: Worldwide Sales of Various Types of Insulin, 2015 (US$ Billions)
Table 3: Top Insulin Pump Comparisons
Table 4: Comparison of Insulin Pumps and Insulin Pens
Table 5: Europe Diabetes Statistics
Table 6: North America Diabetes Statistics
Table 7: China Diabetes Statistics
Table 8: Prices of Popular Insulins
Table 9: Proportion of Undiagnosed Diabetic Population Aged (20-79 years), 2015
Table 10: Coverage of Popular Insulin Drug Brands
Table 11: Novo Nordisk – Diabetes R&D Pipeline
Table 12: Sanofi Aventis Diabetes Pipeline
Table 13: Eli Lilly and Company Clinical Development Pipeline
Table 14: Merck & Co. Product Pipeline
List of Figures
Figure 1: Rockville Research – Research Methodology
Figure 2: Top ten countries/territories for Number of Adults with Diabetes
Figure 3: Global Diabetes Care Market by Treatment Class, 2011-15 (US$ Millions)
Figure 4: Insulin Production and Action
Figure 5: Global Insulin Market Size by Value, 2011-16E (US$ Billions)
Figure 6: Global Insulin Market Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 7: Global Insulin Market Share by Type (2015)
Figure 8: Global Insulin Market (Volume) Share by Segment (2016)
Figure 9: Global Insulin Market (Volume) Share by Region (2015)
Figure 10: Global Insulin Syringes Market Size by Value, 2014-22E (US$ Billions)
Figure 11: Global Insulin Pumps Market Size by Value, 2014-22E (US$ Billions)
Figure 12: Global Insulin Pens Market Size by Value, 2014-22E (US$ Billions)
Figure 13: Global Insulin Injectors Market Size by Value, 2014-22E (US$ Billions)
Figure 14: Global Insulin Delivery Devices Market Share by Product, 2014-22E (US$ Million)
Figure 15: Global Insulin Delivery Devices Market Share by End-User, 2016 & 2022E
Figure 16: Insulin Delivery Devices Market Share by Region (2015)
Figure 17: Global Insulin Delivery Devices Market Share by Region, 2016 & 2022E
Figure 18: Europe - Insulin Market Size by Value, 2011-16E (US$ Billions)
Figure 19: Europe - Insulin Market Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 20: Europe – Insulin Market Share by Insulin Type (2015)
Figure 21: The US - Insulin Market Size by Value, 2011-16E (US$ Billion)
Figure 22: The US - Insulin Market Size by Value Forecasted, 2017E-22E (US$ Billion)
Figure 23: The US – Insulin Market (Volume) Share by TRx, 2011 & 2015
Figure 24: The US – Insulin Market Share by Insulin Type (2015)
Figure 25: China - Insulin Market Size by Value, 2011-16E (US$ Billion)
Figure 26: China - Insulin Market Size by Value Forecasted, 2017E-22E (US$ Billion)
Figure 27: China – Insulin Market Share by Insulin Type (2015)
Figure 28: Worldwide Insulin Price Comparison, Cost per vial of Insulin (Feb’2016)
Figure 29: Worldwide Insulin Cost Increment, 2005 vs. 2015
Figure 30: Cost of Insulin, Jul’1996 – Jul’2016
Figure 31: Intelligent Insulin Pens Connectivity through Different Methods
Figure 32: Worldwide Diabetes Incidence by Region, 2015 & 2040E (Millions)
Figure 33: Prevalence of people with diabetes by age and sex, 2015
Figure 34: Global Obese Population, 2000-2016
Figure 35: Global Diabetes Care Market (Value) Share by Competitors (2016)
Figure 36: Global Modern Insulin Volume Market Share by Competitors (2016)
Figure 37: Global Insulin Unit Share by Drug Brands (2016)
Figure 38: Global Basal Insulin Market Share by Drug Brands (2015)
Figure 39: Global Rapid-Action Insulin Market Share by Drug Brands (2015)
Figure 40: Novo Nordisk Diabetes and Obesity Care Sales by Segment, FY2012-FY2016 (US$ Billion)
Figure 41: Sanofi Aventis Net Sales, FY2012-FY2016 (US$ Billion)
Figure 42: Merck & Co. Revenue by Business Segment (FY2016)
Figure 43: Merck & Co. Net Sales, FY2012-FY2016 (US$ Billion)
Novo Nordisk, Sanofi Aventis, Eli Lilly and Company; and Merck & Co.
*If Applicable.
Links
[1] https://www.marketresearchreports.com/countries/global[2] https://www.marketresearchreports.com/countries/north-america[3] https://www.marketresearchreports.com/countries/caribbean[4] https://www.marketresearchreports.com/countries/europe[5] https://www.marketresearchreports.com/countries/china[6] https://www.marketresearchreports.com/medical-devices[7] https://www.marketresearchreports.com/healthcare[8] https://www.marketresearchreports.com/country-overview-pharma-healthcare[9] https://www.marketresearchreports.com/pharma-healthcare